Yasmin Samra Email & Phone Number

New York, Ny, Us

Seattle, Wa, Us

Enabled the establishment and drove the growth of PBM and Payer partnerships to becoming a lead growth driver for Amazon Pharmacy, working with customer centric Payers and PBMs. Led RFP, sales and finalist presentations, contract negotiations, implementation and account management. Promoted from individual business development lead to a leader of leaders within 2 years, overseeing two organizations: Account Management and Business Development tech teams. Helped shape the Amazon Pharmacy customer experience, since joining shortly after launch, through insights and being the voice of our Partners and their members.

Morristown, Nj, Us

• Key contributor to the due diligence of the vendor evaluation and insourcing/outsourcing for the pre-launch of IngenioRX.• Established product organization from the ground up, recruited 20 individuals, and built products that enabled sales growth and op gain.• Leveraged cross-functional partnerships and executive alignment that drove commercial, Medicare, Medicaid, and stand-alone business growth.• Championed knowledge sharing, ideation challenges, and support toward advancing accountability that instituted a culture of customer-focused innovation.• Owned the shadow product P&L comprised of new and legacy products that included an innovative pharmacy network and a virtual pharmacist premiere program that secured $123M across three years with a capital investment of $6.1M.• Spearheaded the zipdrug acquisition and integration that secured a best in class patient experience and novel network strategy.

Indianapolis, Indiana, Us

• Built team that targeted medical pharmacy integration analytics to establish marketing proof points and support clinical benefits; team published 3-year integration study results.• Secured new business by creating a financial guarantee that was aligned with the value of integration and the leveraging of predictive modeling and artificial intelligence.• Artfully negotiated with pharmacy retailers within Medicare that achieved $35M without forfeiting member access and advanced the implementation of a new Medicaid network that delivered $20M in incremental value with zero interruptions to service.

• Employed deep knowledge of state and federal regulations to introduce strategies that aligned the complex Medicare Medicaid demonstration pilot.• Collaborated with the Innovation Lab to launch new digital strategy, patient adherence, and clinical solutions products that improved patient outcomes and financial savings.• Headed the full lifecycle of a $2M healthcare reform initiative, including mobilizing a cross-functional core team, executing analysis of patient populations, and identifying barriers for IT implementation.

Owner of Medicare End-Stage Renal Disease and Hospice program- Review and analysis of CMS guidance to ensure any changes were implemented timely and within budget- Cross-functional lead on IT projects required to reflect guidance changes and meet client needs- Communicated to clients on key strategic initiatives and provided in-depth explanation of the program

Collaborated with numerous internal IT and operational areas across the organization to implement the complex CMS requirement of short-cycle fill program at long term care pharmacies timely and within budgetMedicare product owner of Part B, Star Ratings, coverage gap, EGWP, and SPL

• Assisted patients in choosing best-in-class therapy in safety and efficacy, contraindications, cost-savings, third-party reimbursement, administration route and convenience. Processed > 200 prescriptions/day.• Assumed pharmacy with high population of Cardiovascular, Diabetes, Oncology, and Neurologic disorders.

• Created a prior authorization rule on smoking cessation products ($1.5 Bn market) using comparative valuation models in Excel.• Critiqued clinical trials of newly approved drugs verses generic and brand competition to decide level reimbursement.• Upon the release of black box warning on Amgen’s Aranesp®, evaluated clinical trial results and met with key ®Amgen contacts to comprehensively reflect the safety warnings in the coverage criteria.

New York, New York, Us

• Conducted fundamental research by attending industry conferences and interviewing industry practitioners. Wrote industry analysis reports on both oncology and obesity drug market.• Designed and updated financial models for four mid-cap biotech companies based on company filings, guidance, and research. Analyzed financial statements and performed discounted cash flow (DCF) and comparable company valuations.• Participated in earnings calls and contributed to developing notes and comments.

• Using Minitab® statistical analysis software, analyzed data to highlight areas needing improvement and strengths. • Researched and compared raw materials to recommend those that were most compatible with each manufacturing process.